New RNA tool may reveal best heated chemo for rare abdominal cancer
NCT ID NCT06839378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested a new method to see how well two different heated chemotherapy regimens work against pseudomyxoma peritonei, a rare abdominal cancer. Researchers injected a special form of chemotherapy (5-FU) before surgery to label newly made RNA in tumor cells. After surgery, patients received either cisplatin alone or cisplatin plus docetaxel as heated chemotherapy. By comparing RNA changes in tumor samples before and after treatment, the study aimed to identify which regimen affects cancer cells more. The 36 participants were adults aged 18-75 with confirmed disease who were eligible for surgery and heated chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 5-fluorouracil, cisplatin, docetaxel
- What this could lead to
- If successful, this could help doctors choose the most effective heated chemotherapy regimen for pseudomyxoma peritonei and identify new treatment targets.
- What could go wrong
- This is a very small, early-stage study (36 people) that only looks at RNA changes, not patient outcomes like survival. The results may not translate into better treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
36 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-75 years old, regardless of gender and race; * Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment; * KPS score ≥ 60, with expected survival time more than 12 months; * The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function; * No history of allergy to biological products; * No serious bacterial or viral infection; * Non-pregnancy and lactation; * The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment. Exclusion Criteria: * Highly allergic or with a history of severe allergies, especially to biological products; * Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination; * Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation; * T-lymphocyte carcinoma/tumor; * Patients with systemic infection or severe local infection requiring anti-infection treatment; * Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs; * Coagulation disorders (e.g., hemophilia); * Infectious diseases (e.g. HIV, RPR, active TB, etc.); * Pregnant or lactating women, or women who have pregnancy plans within half a year; * Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation; * Patients with severe autoimmune diseases; * Any life-threatening disease, physical condition or organ system dysfunction that the researcher believes may damage the safety of subjects and expose the research results to unnecessary risks; Drug-dependent persons; * Patients and/or authorized family members who refuse or do not actively sign the informed consent; * Participants in other clinical studies within 3 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pseudomyxoma peritonei are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy during surgery extend life for peritoneal cancer patients?
- Patient stories could unlock new treatments for rare appendix cancer
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Common diabetes drug may slow rare abdominal cancer
- Lower dose of heated chemo may be just as effective for rare abdominal cancer
- Keeping patients at the right temperature during surgery may protect their brain